AAAAAA

   
Results: 1-14 |
Results: 14
Politics, politics - Introduction
Authors: Perrier, H
Citation: H. Perrier, Politics, politics - Introduction, REV FR ETUD, (87), 2001, pp. 3-6
Onset of coeliac disease and interferon treatment
Authors: Bourliere, M Oules, V Perrier, H Mengotti, C
Citation: M. Bourliere et al., Onset of coeliac disease and interferon treatment, LANCET, 357(9258), 2001, pp. 803-804
Investigation of the in vitro metabolism profile of a phosphodiesterase-IVinhibitor, CDP-840: Leading to structural optimization
Authors: Li, C Chauret, N Trimble, LA Nicoll-Griffith, DA Silva, JM Macdonald, D Perrier, H Yergey, JA Parton, T Alexander, RP Warrellow, GJ
Citation: C. Li et al., Investigation of the in vitro metabolism profile of a phosphodiesterase-IVinhibitor, CDP-840: Leading to structural optimization, DRUG META D, 29(3), 2001, pp. 232-241
Synthesis of rofecoxib, (MK 0966, Vioxx((R)) 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2
Authors: Therien, M Gauthier, JY Leblanc, Y Leger, S Perrier, H Prasit, P Wang, ZI
Citation: M. Therien et al., Synthesis of rofecoxib, (MK 0966, Vioxx((R)) 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2, SYNTHESIS-S, (12), 2001, pp. 1778-1779
Hunting the emesis and efficacy targets of PDE4 inhibitors: Identificationof the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ)
Authors: Macdonald, D Perrier, H Liu, S Laliberte, F Rasori, R Robichaud, A Masson, P Huang, Z
Citation: D. Macdonald et al., Hunting the emesis and efficacy targets of PDE4 inhibitors: Identificationof the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ), J MED CHEM, 43(21), 2000, pp. 3820-3823
Covert transmission of hepatitis C virus during bloody fisticuffs
Authors: Bourliere, M Halfon, P Quentin, Y David, P Mengotti, C Portal, I Khiri, H Benali, S Perrier, H Boustiere, C Jullien, M Lambot, G
Citation: M. Bourliere et al., Covert transmission of hepatitis C virus during bloody fisticuffs, GASTROENTY, 119(2), 2000, pp. 507-511
Echocardiographic diagnosis of carcinoid tumours.
Authors: Avierinos, JF Habib, G Garcia, M Lefevre, J Medail, C Dufaut, F Philip, E Ambrosi, P Perrier, H Luccioni, R
Citation: Jf. Avierinos et al., Echocardiographic diagnosis of carcinoid tumours., ARCH MAL C, 93(3), 2000, pp. 277-283
Substituted furans as inhibitors of the PDE4 enzyme
Authors: Perrier, H Bayly, C Laliberte, F Huang, Z Rasori, R Robichaud, A Girard, Y Macdonald, D
Citation: H. Perrier et al., Substituted furans as inhibitors of the PDE4 enzyme, BIOORG MED, 9(3), 1999, pp. 323-326
The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Authors: Prasit, P Wang, Z Brideau, C Chan, CC Charleson, S Cromlish, W Ethier, D Evans, JF Ford-Hutchinson, AW Gauthier, JY Gordon, R Guay, J Gresser, M Kargman, S Kennedy, B Leblanc, Y Leger, S Mancini, J O'Neill, GP Ouellet, M Percival, MD Perrier, H Riendeau, D Rodger, I Tagari, P Therien, M Vickers, P Wong, E Xu, LJ Young, RN Zamboni, R Boyce, S Rupniak, N Forrest, N Visco, D Patrick, D
Citation: P. Prasit et al., The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, BIOORG MED, 9(13), 1999, pp. 1773-1778
Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins
Authors: Fabien, N Moreira, A Lavergne, JP Desbos, A Surgey, P de Olivera, CA Gonzalo, P Venot, A Bienvenu, J Perrier, H Reboud, JP Monier, JC
Citation: N. Fabien et al., Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins, J AUTOIMMUN, 13(1), 1999, pp. 103-110
[1,3] and [3,3] rearrangements of 3-amino-1,5-hexadienes: Solvent effect on the regioselectivity
Authors: Dobson, HK LeBlanc, R Perrier, H Stephenson, C Welch, TR Macdonald, D
Citation: Hk. Dobson et al., [1,3] and [3,3] rearrangements of 3-amino-1,5-hexadienes: Solvent effect on the regioselectivity, TETRAHEDR L, 40(16), 1999, pp. 3119-3122
Solid phase parallel synthesis of highly substituted thiophene derivativesand identification of novel phosphodiesterase-4 (PDE-4) inhibitors
Authors: Han, YX Giroux, A Lepine, C Laliberte, F Huang, Z Perrier, H Bayly, CI Young, RN
Citation: Yx. Han et al., Solid phase parallel synthesis of highly substituted thiophene derivativesand identification of novel phosphodiesterase-4 (PDE-4) inhibitors, TETRAHEDRON, 55(39), 1999, pp. 11669-11685
Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
Authors: Chan, CC Boyce, S Brideau, C Charleson, S Cromlish, W Ethier, D Evans, J Ford-Hutchinson, AW Forrest, MJ Gauthier, JY Gordon, R Gresser, M Guay, J Kargman, S Kennedy, B Leblanc, Y Leger, S Mancini, J O'Neill, GP Ouellet, M Patrick, D Percival, MD Perrier, H Prasit, P Rodger, I Tagari, P Therien, M Vickers, P Visco, D Wang, Z Webb, J Wong, E Xu, LJ Young, RN Zamboni, R Riendeau, D
Citation: Cc. Chan et al., Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J PHARM EXP, 290(2), 1999, pp. 551-560
Liquid-phase synthesis with solid-phase workup: Application to multistep and combinatorial syntheses
Authors: Perrier, H Labelle, M
Citation: H. Perrier et M. Labelle, Liquid-phase synthesis with solid-phase workup: Application to multistep and combinatorial syntheses, J ORG CHEM, 64(6), 1999, pp. 2110-2113
Risultati: 1-14 |